title: Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States.
abstract: Antihypertensive treatment regimen persistence and compliance were measured using a retrospective cohort study of pharmacy claims data. Newly treated patients receiving monotherapy with angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), beta-blockers (BBs), or diuretics were followed for 1 year (N=242,882). A higher proportion of ARB patients (51.9%) were persistent in taking prescribed medication compared with those in the ACEI (48.0%), BB (40.3%), CCB (38.3%), and diuretic groups (29.9%). Compared with patients receiving diuretics, those receiving ARBs (hazard ratio [HR], 0.593; P<.0001), ACEIs (HR, 0.640; P<.0001), CCBs (HR, 0.859; P<.0001), and BBs (HR, 0.819; P<.0001) were all less likely to discontinue therapy. Compliance was similar in ACEI and ARB patients, but patients receiving ARBs and ACEIs had better compliance than those receiving BBs, CCBs, or diuretics. The lesser degree of compliance and persistence observed in patients receiving diuretics compared with other antihypertensive medications may have public health as well as cost implications.
authors.affiliation: MedImpact Healthcare Systems, Inc, San Diego, CA 92131, USA. bimal.patel@medimpact.com
authors.forename: Bimal V
authors.initials: BV
authors.lastname: Patel
authors.forename: Rosemay A
authors.initials: RA
authors.lastname: Remigio-Baker
authors.forename: Devi
authors.initials: D
authors.lastname: Mehta
authors.forename: Patrick
authors.initials: P
authors.lastname: Thiebaud
authors.forename: Feride
authors.initials: F
authors.lastname: Frech-Tamas
authors.forename: Ronald
authors.initials: R
authors.lastname: Preblick
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000191:economics / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000191:economics / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000145:classification / Q000191:economics / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000191:economics / Q000627:therapeutic use; D004232:Diuretics / Q000191:economics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D012189:Retrospective Studies; D016896:Treatment Outcome; D014481:United States